Printer Friendly

CAMBRIDGE BIOTECH LICENSES ITS STIMULON ADJUVANT TO AMERICAN CYANAMID

 WORCESTER, Mass., May 3 /PRNewswire/ - Cambridge Biotech Corporation (NASDAQ: CBCX) announced today that it has entered into a definitive agreement with American Cyanamid Company (NYSE:ACY) that grants Cyanamid the right to use Cambridge Biotech's patented Stimulon (TM) QS-21 adjuvant in a number of vaccines. Cambridge Biotech's adjuvant is a potent immune system stimulant that enhances protective immune response to vaccinations.
 Under the agreement, Cyanamid's Lederle-Praxis Biologicals division will have the right to use Cambridge Biotech's Stimulon (TM) QS-21 adjuvant in vaccines for treatment or prevention of specific viral and bacterial infections. Cyanamid has paid an initial license fee and will make additional license fee payments over the next several years to Cambridge Biotech upon the achievement of development milestones. In addition, Cambridge Biotech agreed to sell bulk adjuvant to Cyanamid for formulation into vaccines. Cyanamid will pay Cambridge Biotech royalties on any sales of products containing Cambridge Biotech's adjuvant.
 An adjuvant is a key component of a vaccine that boosts its ability to elicit strong responses from the immune system. Like the microprocessor chip in a computer, the adjuvant functions as a power builder within the vaccine, increasing its ability to prevent and treat disease. Cambridge Biotech's Stimulon (TM) QS-21 adjuvant holds the promise of being the next "universal adjuvant" serving next generation vaccines.
 Patrick J. Leonard, President and Chief Executive Officer of Cambridge Biotech, commented, "Our agreement with American Cyanamid Company strengthens our strategy for licensing the adjuvant to leading pharmaceutical vaccine developers. Cyanamid's Lederle-Praxis Biologicals division is a world leader in vaccine development. We look forward to a long and mutually productive association, and we hope that our QS-21 adjuvant can contribute to new, cost-effective vaccines for adults and children worldwide."
 Cambridge Biotech Corporation is a leading diagnostics and therapeutics company involved in infectious diseases. The company is developing vaccines, adjuvants and diagnostics for humans and animals.
 American Cyanamid Company is a research-based life sciences and chemical company which discovers and develops medical, agricultural and chemical products, and manufactures and markets them throughout the world.
 The Lederle-Praxis Biologicals division is a leading developer, manufacturer and distributor of several important child and adult vaccines. Vaccines currently available from Lederle-Praxis Biologicals include those to prevent polio, diphtheria, tetanus, pertussis, Haemophilus b meningitis, viral influenza and pneumococcal pneumonia.
 -0- 5/3/93
 /CONTACT: Frederick V. Casselman, Vice President of Legal Affairs & Technology Licensing, Cambridge Biotech Corporation, 508-797-5777/
 (CBCX ACY)


CO: Cambridge Biotech Corporation; American Cyanamid Company ST: Massachusetts IN: MTC SU:

DH -- NE005 -- 3560 05/03/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:420
Previous Article:MAY ISSUE OF "HIGHLIGHTS FOR CHILDREN" IS 500TH FOR POPULAR MAGAZINE FOR KIDS
Next Article:AMERICAN RE-INSURANCE COMPANY STRENGTHENS LONG-TERM ALLIANCE WITH MOLTEN METAL TECHNOLOGY THROUGH EQUITY INVESTMENT AND STRATEGIC SERVICES
Topics:


Related Articles
CAMBRIDGE BIOTECH CORPORATION SIGNS INTENT TO ACQUIRE MINORITY STAKE IN IMMUCELL CORPORATION
CAMBRIDGE BIOTECH CORPORATION AND PASTEUR MERIEUX IN INFLUENZA VACCINE PARTNERSHIP
CAMBRIDGE BIOTECH CORPORATION AND SMITHKLINE BEECHAM SIGN VACCINE ALLIANCE
CAMBRIDGE BIOTECH CORPORATION AND GENENTECH, INC. AGREE TO VACCINE ALLIANCE
RESULTS OF HUMAN PHASE I TRIAL OF CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT REPORTED
CAMBRIDGE BIOTECH REPORTS 1992 RESULTS
CAMBRIDGE BIOTECH CORPORATION'S STIMULON ADJUVANT IN PHASE I TRIAL WITH GENENTECH HIV-1 VACCINE
RIBI, AMERICAN CYANAMID COMPLETE CO-EXCLUSIVE ADJUVANT LICENSE/SUPPLY AGREEMENTS
HEARING SET FOR JULY 15, 1996 ON CONFIRMATION OF CAMBRIDGE BIOTECH'S PLAN OF REORGANIZATION
Aquila QS-21 Adjuvant Key Component of Promising Malaria Vaccine Reported in The New England Journal of Medicine

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters